Tag Archives: India

Patent Evergreening in India: Response from the Other Side

Plant

Thank you Adriana for commenting on my article Patent “Ever-Greening”: Novartis Confronts Patent Myth in India.  Before I respond, here is your full comment: Adriana says: While patients in India may still be able to access a generic form of off-patent imatinib mesylate (Glivec) if Novartis wins their legal challenge (because this “original form” was never patented in India due to India’s patent law not allowing product patents on medicines prior to 2005), a legal Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor

india-btn

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Meet 2011′s Buzz of BIO Winner, Amrita Therapeutics

BuzzofBIOLogo

2011 Buzz of BIO Health Winner Amrita Therapeutics is a bio-pharma discovery company based in Ahmedabad, Gujarat, pursuing the development of novel, multiple disease targeting therapies for cancer. Last year, they won the Buzz of BIO Contest for the 2011 BIO International Convention, where industry executives and leaders voted on their favorite biotech companies. BIO recently spoke with Susan Finston, the CEO of Amrita Therapeutics, to get their thoughts on the contest, last year’s BIO Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Patent “Ever-Greening”: Novartis Confronts Patent Myth in India

Pine

India’s ‘increased efficacy’ patentability requirement for medicines prevents an improved form of a known drug from receiving a patent unless the new form is significantly more effective than the previously-known form. This provision aims to accomplish one task: stop patent “ever-greening.”  This issue has risen to prominence lately as the New York Times reports on the Novartis suit challenging patent ever-greening requirements in India’s Supreme Court. So what is patent ever-greening?  Opponents claim that corporations Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

BioWorld previews BIO India: India Emerges as Global Player via Multinational Partnering

BioWorld’s Tom Wall interviewed BIO’s Alan Eisenberg (subscription required) on what attendees can expect at this week’s BIO India International Partnering Conference. Interest in India has been strong and attendance at the conference is expected to surpass last year’s event. The population forecasted to grow in the coming years, combined with significant disease burden is a draw for many companies seeking business development and partnering opportunities. BIO India will feature keynote speakers Glenn Saldanha, Chairman Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,